Milan, Italy (August 20, 2025)

Today, MgShell, a MedTech company that aspires to inspire a change in ophthalmology by developing a magnesium-based drug delivery platform capable of reshaping patient care and enhancing treatment adherence for patients suffering from retinal diseases, announced its attendance at 2025 Biometal Symposium and its partecipation as presenter for the workshop Innovation Cluster 3 – Biometals for Innovation in Ocular Treatments.

The event will be held August 25-30, 2025 in Cetraro, Italy, and the workshop is scheduled for Tuesday 26th at 3pm. Marco Ferroni, Chief Executive Officer, Francesco De Gaetano, Chief Technology Officer, and Elena Pepe, R&D Engineer, will be attending the congress with the aim to cement current relationships and establish new ones with academics, experts and strategic partners.

About MgShell:

MgShell, headquartered in Milan, Italy, is a preclinical-stage drug delivery company focused on developing a magnesium-based drug delivery platform capable of reshaping patient care, enhancing treatment adherence for patients suffering from retinal diseases, and lowering healthcare expenses.